Iovance Biotherapeutics Inc. has released a corporate presentation detailing recent advancements and commercial progress in tumor-infiltrating lymphocyte $(TIL)$ therapy for cancer patients. The company reported that over 1,000 patients have been treated with its commercial and clinical TIL products, with more than 85 authorized treatment centers as of the end of 2025. Financial highlights include anticipated fiscal year 2025 revenue in the range of $250 million to $300 million and a gross margin of 43% in the third quarter of 2025. Iovance’s product Amtagvi®, indicated for previously treated advanced melanoma, demonstrated an objective response rate of 31.4%, a median duration of response of 36.5 months, and a five-year overall survival rate of 19.7% based on a pooled analysis. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.